Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
New Strong Buy Stocks for July 26th
08:40am, Wednesday, 26'th Jul 2023
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.
Zymeworks To Host Second Quarter 2023 Results Conference Call
08:30am, Wednesday, 19'th Jul 2023
VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
08:53pm, Tuesday, 11'th Jul 2023
Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of succes
Zymeworks Announces Participation in Upcoming Investor Conference
08:30am, Monday, 03'rd Jul 2023
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced
The 3 Most Undervalued Growth Stocks for Your June Buy List
01:32pm, Sunday, 11'th Jun 2023
If you're willing to attempt a difficult balancing act in seeking out a discount and potentially imminent upside momentum at roughly the same time, these adventurous undervalued growth stocks could be
3 Cheap Growth Stocks That Are Too Good to Pass Up
06:00am, Monday, 05'th Jun 2023
Growth stocks are often expensive in that they trade with high valuations like price-to-earnings (P/E) and price-to-sales (P/S) ratios. Yet, these high valuations might be justified if the company can
Zymeworks Announces Participation in Upcoming Investor Conferences
08:30am, Thursday, 01'st Jun 2023
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced
Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript
10:47pm, Monday, 08'th May 2023
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kenneth Galbraith - Chairman, Chief Executive Officer Neil Klompas - President, Chief Operati
Zymeworks Announces Participation in Upcoming Investor Conferences
08:30am, Monday, 01'st May 2023
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced t
The 7 Most Undervalued Stocks You Need to Know About
03:38pm, Tuesday, 18'th Apr 2023
Heading into unchartered territory in the market, investors may take comfort in acquiring the most undervalued stocks. Primarily, the less-popular enterprises offer the advantage of being exactly that
Zymeworks: Exciting Short Squeeze Candidate With Large Cash Holdings
01:17am, Monday, 10'th Apr 2023
Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. A significant pipeline, with partners helping to finance drug trials, is wo
Zymeworks Offers Hope for More than Just Long-Term Investors
06:46am, Thursday, 09'th Mar 2023
Zymeworks Inc. (NASDAQ: ZYME) stock is up almost 5% after beating analysts' expectations for revenue and earnings in its March 7, 2023 earnings report. The clinical-stage biopharmaceutical company is
Zymeworks Inc. (ZYME) Q4 2022 Earnings Call Transcript
11:15pm, Tuesday, 07'th Mar 2023
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Chris Astle - Senior Vice President & Chief Financ
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates
06:48pm, Tuesday, 07'th Mar 2023
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks: Completion Of Jazz Deal Provides New Life
05:33am, Thursday, 23'rd Feb 2023
Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response.
